For the three months ended April 30, the company, which has a joint-venture agreement with Life Technologies' Applied Biosystems on mass specs, said its Analytical Technologies revenues fell to $87 million, down from $118 million in Q2 2008.
Using their method, which combines the advantages of in-gel and in-solution approaches, the researchers identified what they said is "to our knowledge … the largest reported proteome in any single experiment."
In a competitive field where deals linking two mass-spec technologies from different vendors are unusual, the partnership could help Bio-Rad make relevant a technology that has failed to capture the interest of the research community.
Some researchers, like Ruedi Aebersold, claim that because tools such as mass specs are in a "perpetual discovery mode, the high-performance application of the [the tools] will remain in specialized labs."
It was not immediately clear whether PerkinElmer would divest all of its proteomics assets or retain a portion of them, though it described them as “discontinued operations” during its fourth-quarter earnings statement.